RxDoctor Payments Data

Jorge Montalvan, MD

Internal Medicine · Boca Raton, FLNPI 1679554596

Payments from drug & device makers

$10,183in general payments, 2019–2025

Across 358 payments — averaging $28.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$990
  • AstraZeneca$843
  • Johnson & Johnson$812
  • GSK$649
  • Amarin Pharma, Inc.$625
  • plus $5K from 47 others

What the payments were for

  • Consulting fees$160%
  • Food & beverage$10,150100%
  • Education$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,183 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$271,614
Medicare patients
391
Services billed
17,132

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$58,613
MounjaroTirzepatide48$56,126
EliquisApixaban39$45,838
JardianceEmpagliflozin35$29,144
ProliaDenosumab12$20,789
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$20,332
JanuviaSitagliptin Phosphate21$20,088
MyrbetriqMirabegron18$15,400
SynthroidLevothyroxine Sodium53$6,191
Icosapent Ethyl12$3,692
Ezetimibe168$3,660
Rosuvastatin Calcium248$2,899
Tresiba Flextouch U-100Insulin Degludec12$2,860
Atorvastatin Calcium257$2,369
Metoprolol Succinate100$1,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$123$58,61347 claims
Lilly USA, LLCMounjaro$297$56,12648 claims
PfizerEliquis$437$45,83839 claims
Boehringer IngelheimJardiance$210$29,14435 claims
AmgenProlia$1,148$20,78912 claims
GSKTrelegy Ellipta$649$20,33226 claims
MerckJanuvia$49$20,08821 claims
Astellas Pharma US IncMyrbetriq$327$15,40018 claims
AbbVieSynthroid$990$6,19153 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →